ArticleNature communications2026
Molecular basis of DosR-dependent transcription activation in Mycobacterium tuberculosis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The transcription activator DosR is a key dormancy regulator controlling latent infection of the worldwide pathogenic Mycobacterium tuberculosis (Mtb), but its molecular mechanism remains unclear. Here we determine the cryo-EM structure of an intact DosR-dependent transcriptional activation complex (DosR-TAC), comprising Mtb RNA polymerase (RNAP), DosR, and the hypoxic promoter DNA. The structure shows that two DosR monomers symmetrically dimerize through the N-terminal receiver domains (DosR_RECs) and the distinct α10 helices from the C-terminal DNA-binding domains (DosR_DBDs). Different from its inhibitory configuration, the functional DosR dimer exhibits significant conformational rearrangements, especially at the linker helix, which enable DosR to simultaneously contact promoter DNA and recruit RNAP by engaging the conserved domains (σ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.